Regulation & Compliance

Planisware targets APAC growth with a new Australian office and two data centers, betting on data sovereignty and AI to win in a competitive market.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

One California firm is rewriting the rules of law with AI and global teams, achieving massive scale. Is this the future of legal services?

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

A new pact on quantum computing and AI safety aims to do more than innovate—it seeks to build a secure, equitable digital world for every citizen.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

A minor share sale by a US giant in a UK tech firm reveals the subtle art of institutional investing and the power of regulatory transparency.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

A Texas utility automated 90% of its collection calls with AI. The real story isn't just efficiency, but how it creates a fairer, more humane process.

A new partnership seeks to unify viewership, channel, and ad data across all 210 US markets, promising unprecedented precision for local advertisers.

The CRA's shift to online-only mail promises efficiency but creates new risks. Are Canadian businesses prepared for the compliance and security challenges?

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

Enterprises struggle to deploy trustworthy AI. Couchbase's new platform, with partners like NVIDIA, offers a blueprint for secure, governed AI in healthcare.

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

A new partnership aims to unify cybersecurity and operations in smart buildings, but can it solve the deep-rooted trust and vulnerability issues?

As community hubs face new threats, advanced AI surveillance offers powerful protection. But what are the costs and ethical lines for Canadian organizations?

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.